Psoríase, comorbidades, terapia e seus efeitos adversos

Mariana Oliveira Axer; Thaís Carvalho Cunha; Leandra Covre Barbosa; Nathânia Aparecida Luna Peron; Ana Luiza Scussulim Florindo Alcure Dias

doi:10.18378/rebes.v13i3.10125

Authors

Mariana Oliveira Axer Afya Faculdade de Ciências Médicas de Ipatinga, Ipatinga, Minas Gerais, Brasil https://orcid.org/0000-0002-7878-6176
Thaís Carvalho Cunha Afya Faculdade de Ciências Médicas de Ipatinga, Ipatinga, Minas Gerais, Brasil https://orcid.org/0000-0001-7522-586X
Leandra Covre Barbosa Afya Faculdade de Ciências Médicas de Ipatinga, Ipatinga, Minas Gerais, Brasil https://orcid.org/0009-0009-5618-7111
Nathânia Aparecida Luna Peron Afya Faculdade de Ciências Médicas de Ipatinga, Ipatinga, Minas Gerais, Brasil https://orcid.org/0009-0000-1897-176X
Ana Luiza Scussulim Florindo Alcure Dias União Educacional do Vale do Aço, Ipatinga, Minas Gerais, Brasil https://orcid.org/0009-0000-0187-5886

DOI:

https://doi.org/10.18378/rebes.v13i3.10125

Abstract

Psoriasis is a chronic inflammatory skin disease that affects 2-3% of the population worldwide, is characterized by erythematous scaly plaques and can involve the joints in the case of arthropathic psoriasis and is associated with significant impairments in physical and mental health due to its impact on daily activities. Objectives: To discuss the comorbidities and treatment of psoriasis and its adverse effects. Methodology: This is a literature review with a qualitative descriptive approach. The search for material took place in September 2023, using the SciELO and PubMed databases. For the search, the following terms (keywords and delimiters) will be used in combination with the "AND" connective, using the following descriptors: "Psoriasis"; "Comorbidity"; "Treatment". Results: Studies have shown that patients with psoriasis have increased hyperlipidemia, hypertension, coronary artery disease, type 2 diabetes and increased body mass index. Therapeutic options for psoriasis include topical therapy, phototherapy or systemic treatment. Mild to moderate psoriasis, for example, can be treated topically with a combination of therapies, while moderate to severe psoriasis usually requires systemic treatment; and the presence of comorbidities such as psoriatic arthritis is also highly relevant in treatment management. Advances in diagnosis and treatment have resulted in a growing number of therapeutic options that can dramatically improve the lives of people with psoriasis. However, the disease is still very common, and treatment and access do not yet meet patients' needs.

Downloads

Download data is not yet available.

References

BOCCATO, V. R. C. Metodologia da pesquisa bibliográfica na área odontológica e o artigo científico como forma de comunicação. Rev. Odontol. Univ. Cidade São Paulo, São Paulo, v. 18, n. 3, p. 265-274, 2006.

BOEHNCKE, W.-H. Etiology and pathogenesis of psoriasis. Rheumatic Disease Clinics, v. 41, n. 4, p. 665-675, 2015.

BOEHNCKE, W.-H.; BOEHNCKE, S.; SCHÖN, M. P. Managing comorbid disease in patients with psoriasis. Bmj, v. 340, 2010.

CAINELLI, T.; GIANNETTI, A.; REBORA, A. Manuale di Dermatologia Medica e Chirurgica; McGraw-Hill Education: Milan, Italy, 2017.

DAND, N. et al. HLA-C* 06: 02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, v. 143, n. 6, p. 2120-2130, 2019.

DOGRA, S. et al. Comparison of overall efficacy and safety of oral versus subcutaneous methotrexate in severe psoriasis. Dermatologic Therapy, v. 35, n. 8, p. e15656, 2022.

FLEMING, P. et al. The prevalence of anxiety in patients with psoriasis: a systematic review of observational studies and clinical trials. Journal of the European Academy of Dermatology and Venereology, v. 31, n. 5, p. 798-807, 2017.

FRANCESCO, M. A.; CARUSO, A. The gut microbiome in psoriasis and crohn’s disease: is its perturbation a common denominator for their pathogenesis?. Vaccines, v. 10, n. 2, p. 244, 2022.

GERDES, S.; MROWIETZ, U.; BOEHNCKE, W.-H. Comorbidity in psoriasis. Der Hautarzt, v. 67, p. 438-444, 2016.

GRIFFITHS, C. E.; BARKER, J. N. Pathogenesis and clinical features of psoriasis. The Lancet, v. 370, n. 9583, p. 263–271, jul. 2007.

LEWIS-BECK, C. et al. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient preference and adherence, p. 199-205, 2013.

MAHIL, S. K. et al. Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis. British Journal of Dermatology, v. 183, n. 4, p. 638-649, 2020.

MARANI, A. et al. Comorbidades metabólicas e doenças cardiovasculares na psoríase pediátrica: uma revisão narrativa. In: Saúde . MDPI, p. 1190, 2022.

MEHTA, N. N. et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography–computed tomography (FDG-PET/CT): a pilot study. Archives of dermatology, v. 147, n. 9, p. 1031-1039, 2011.

MROWIETZ, U. et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Archives of dermatological research, v. 303, p. 1-10, 2011.

NANI, P. et al. Pharmacogenetic Analysis of the MIR146A rs2910164 and MIR155 rs767649 Polymorphisms and Response to Anti-TNF Treatment in Patients with Crohn’s Disease and Psoriasis. Genes, v. 14, n. 2, p. 445, 2023.

NAST, A. et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris–Part 2: specific clinical and comorbid situations. Journal of the European Academy of Dermatology and Venereology, v. 35, n. 2, p. 281-317, 2021.

ORLANDO, G. et al. Psoríase e doenças cardiovasculares: uma conversa cruzada imunomediada?. Fronteiras em Imunologia , v. 13, p. 868277, 2022.

PACIFICO, A. et al. Photoadaptation to ultraviolet B TL01 in psoriatic patients. Journal of the European Academy of Dermatology and Venereology, v. 34, n. 8, p. 1750-1754, 2020.

PARISI, R. et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. Journal of Investigative Dermatology, v. 133, n. 2, p. 377-385, 2013.

RACHAKONDA, T. D.; SCHUPP, C. W.; ARMSTRONG, A. W. Psoriasis prevalence among adults in the United States. Journal of the American Academy of Dermatology, v. 70, n. 3, p. 512-516, 2014.

RAHARJA, A.; MAHIL, S. K.; BARKER, J. N. Psoriasis: a brief overview. Clinical Medicine, v. 21, n. 3, p. 170, 2021.

RAPP, Stephen R. et al. Psoriasis causes as much disability as other major medical diseases. Journal of the American Academy of Dermatology, v. 41, n. 3, p. 401-407, 1999.

RENDON, A.; SCHÄKEL, K. Psoriasis pathogenesis and treatment. International journal of molecular sciences, v. 20, n. 6, p. 1475, 2019.

SAMPOGNA, F.; TABOLLI, S.; ABENI, D. Living with psoriasis: prevalence of shame, anger, worry, and problems in daily activities and social life. Acta dermato-venereologica, v. 92, n. 3, p. 299-303, 2012.

SMITH, C. H. et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update. British Journal of Dermatology, v. 183, n. 4, p. 628-637, 2020.

SOMMER, D. M. et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Archives of dermatological research, v. 298, p. 321-328, 2007.

SZEPIETOWSKI, J. C.; REICH, A. Pruritus in psoriasis: An update. European Journal of Pain, v. 20, n. 1, p. 41-46, 2016.

WAN, J. et al. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. Bmj, v. 347, 2013.

YEUNG, H. et al. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA dermatology, v. 149, n. 10, p. 1173-1179, 2013.

Psoriasis, comorbidities, therapy and its adverse effects

Authors

DOI:

Abstract

Downloads

References

Downloads

Published

How to Cite

Issue

Section

License

Make a Submission

Language

Current Issue

Keywords

Information